Agape ATP Corp. Announces Executive and Director Changes

TL;DR

Agape ATP Corp. shakes up exec team: Dr. Li out as director, in as CSO; Kai Chen is new CFO, Yuhui Chen is COO.

AI Summary

Agape ATP Corp. announced changes effective October 1, 2024, including the departure of Director Dr. Jian Li and the appointment of Dr. Jian Li as Chief Scientific Officer. Additionally, the company appointed Mr. Kai Chen as Chief Financial Officer and Ms. Yuhui Chen as Chief Operating Officer. These changes are part of the company's ongoing operational adjustments.

Why It Matters

Key executive and director changes can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: medium — Executive changes can introduce uncertainty regarding future strategy and execution, warranting closer monitoring.

Key Players & Entities

• Agape ATP Corp (company) — Registrant
• Dr. Jian Li (person) — Departing Director and Appointed Chief Scientific Officer
• Kai Chen (person) — Appointed Chief Financial Officer
• Yuhui Chen (person) — Appointed Chief Operating Officer
• October 1, 2024 (date) — Effective date of changes
• October 7, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ATPC NASDAQ Capital Mark

Filing Documents

• form8-k.htm (8-K) — 36KB
• 0001493152-24-039653.txt ( ) — 209KB
• atpc-20241007.xsd (EX-101.SCH) — 3KB
• atpc-20241007_lab.xml (EX-101.LAB) — 33KB
• atpc-20241007_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On October 1, 2024, Mr. Chee Chin Aik ("Mr. Chee") resigned as our independent director of the Board of Directors (the "Board"), the chairman of the nominating and governance committee and as a member of the audit and compensation committees of the Agape ATP Corporation (the "Company"), effective from October 1, 2024. On October 1, 2024, Dr. Ni Luh Dharma Kerti Natih (Dr. Natih) was appointed as an independent director of the Board to fill the vacancy left by Mr. Chee's resignation. Prior to joining the Company, Dr. Natih has more than 20 years of experience in the field of health services. Dr. Natih has been served as a Certified Hospital Accreditation Surveyor at KARS and Ministry of Health of Indonesia from 2000 to present. Prior to joining the Company, Dr. Natih served as a director at the Department of Hospital Planning and Operations of Ngoerah General Hospital (formerly known as RSUP Sanglah Denpasar) in Bali, Indonesia from 2000 to 2023. From 2023 to 2024, Dr. Natih served as a director at the Department of Medical and Nursing Care of RSP Goenawan in Cisarua Bogor, Indonesia. Dr. Natih completed her early University studies at Gadjah Mada University in Yogyakarta, Indonesia in the Faculty of Medicine. She graduated with a Master of Public Health (Health Services Management) from Flinders University in Adelaide, Australia in 2006. Dr. Natih is a Certified Hospital Accreditation Expert at KARS Indonesia and a Certified Hospital Accreditation Surveyor Competence at the Ministry of Health of Indonesia. Dr. Natih has no family relationships with any of the executive officers or directors of the Company. There have been no transactions in the past two years to which the Company or any of its subsidiaries was or is to be a party, in which Dr. Natih had, or will have, a direct or indirect material interes

View Full Filing

View this 8-K filing on SEC EDGAR